Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
22.52
Dollar change
+1.14
Percentage change
5.33
%
IndexRUT P/E- EPS (ttm)-6.07 Insider Own13.37% Shs Outstand26.60M Perf Week-7.89%
Market Cap602.64M Forward P/E- EPS next Y-5.99 Insider Trans-4.58% Shs Float23.18M Perf Month-12.75%
Income-163.62M PEG- EPS next Q-1.56 Inst Own103.32% Short Float17.84% Perf Quarter3.02%
Sales17.16M P/S35.12 EPS this Y-3.90% Inst Trans4.79% Short Ratio14.13 Perf Half Y21.93%
Book/sh3.31 P/B6.80 EPS next Y5.20% ROA-30.79% Short Interest4.14M Perf Year4.26%
Cash/sh14.61 P/C1.54 EPS next 5Y- ROE-93.44% 52W Range13.36 - 27.50 Perf YTD5.14%
Dividend Est.- P/FCF- EPS past 5Y-19.45% ROI-39.43% 52W High-18.11% Beta-0.29
Dividend TTM- Quick Ratio10.87 Sales past 5Y172.96% Gross Margin86.15% 52W Low68.56% ATR (14)1.34
Dividend Ex-Date- Current Ratio10.87 EPS Y/Y TTM-32.73% Oper. Margin-915.50% RSI (14)45.18 Volatility7.53% 5.77%
Employees117 Debt/Eq3.73 Sales Y/Y TTM66.78% Profit Margin-953.66% Recom1.50 Target Price44.43
Option/ShortYes / Yes LT Debt/Eq3.71 EPS Q/Q-71.00% Payout- Rel Volume1.61 Prev Close21.38
Sales Surprise137.89% EPS Surprise0.67% Sales Q/Q32.27% EarningsMar 11 AMC Avg Volume292.61K Price22.52
SMA20-5.99% SMA50-6.09% SMA20012.99% Trades Volume470,804 Change5.33%
Date Action Analyst Rating Change Price Target Change
Mar-12-24Upgrade Wedbush Neutral → Outperform $20 → $34
Feb-26-24Initiated BTIG Research Buy $55
Feb-21-24Initiated Stifel Buy $50
Feb-16-24Initiated Piper Sandler Overweight $80
May-22-23Upgrade JP Morgan Underweight → Neutral $31 → $30
May-18-23Initiated TD Cowen Outperform
Jan-06-23Downgrade Raymond James Outperform → Mkt Perform
Nov-01-22Upgrade Guggenheim Neutral → Buy $44
Sep-19-22Resumed H.C. Wainwright Buy $35
Sep-13-22Downgrade Truist Buy → Hold $50 → $28
Mar-14-24 12:00PM
09:55AM
Mar-11-24 05:30PM
04:15PM
Feb-29-24 09:15AM
10:00AM Loading…
Feb-28-24 10:00AM
Feb-22-24 04:00AM
Feb-19-24 05:54AM
Jan-31-24 09:15AM
Jan-12-24 03:02PM
Dec-07-23 09:55AM
Nov-27-23 04:15PM
Nov-14-23 09:35AM
Nov-07-23 04:15PM
Nov-04-23 05:41AM
04:15PM Loading…
Nov-02-23 04:15PM
Nov-01-23 09:15AM
Oct-11-23 09:15AM
Oct-09-23 08:27AM
08:15AM
08:05AM
08:00AM
Sep-19-23 03:01PM
Sep-18-23 04:15PM
Sep-12-23 09:15AM
Aug-07-23 04:15PM
Jul-31-23 01:34PM
Jul-04-23 06:22AM
May-30-23 04:15PM
May-24-23 06:01AM
01:44AM Loading…
May-22-23 01:44AM
May-11-23 05:35PM
04:15PM
May-04-23 09:55AM
May-02-23 09:15AM
Apr-30-23 09:47AM
Apr-27-23 10:02AM
Apr-26-23 10:02AM
Apr-14-23 03:13AM
Apr-06-23 04:15PM
Apr-03-23 07:14AM
Mar-27-23 06:50PM
Mar-01-23 05:45PM
04:05PM
Feb-27-23 04:05PM
Jan-13-23 09:00AM
Jan-05-23 04:05PM
Dec-22-22 09:33AM
Dec-02-22 09:00AM
Nov-21-22 01:56PM
Nov-11-22 05:19AM
Nov-09-22 02:10PM
Nov-08-22 05:55PM
04:05PM
Oct-25-22 06:28AM
Oct-13-22 09:55AM
Oct-06-22 11:02AM
Oct-05-22 11:31AM
09:00AM
Sep-26-22 08:00AM
Sep-19-22 02:02PM
Sep-14-22 06:14AM
Sep-12-22 11:18AM
07:30AM
Sep-02-22 01:41PM
Sep-01-22 09:58AM
Aug-31-22 04:15PM
Aug-10-22 06:28AM
Aug-08-22 05:35PM
04:05PM
Aug-05-22 04:00PM
Jul-08-22 07:22AM
Jun-24-22 06:31AM
Jun-02-22 04:05PM
May-10-22 06:09AM
May-04-22 06:55PM
04:15PM
Apr-28-22 08:48AM
Apr-27-22 04:15PM
Apr-26-22 07:05AM
Mar-21-22 04:15PM
Mar-15-22 11:35AM
08:07AM
Mar-14-22 04:20PM
Mar-09-22 05:09AM
Mar-07-22 10:05AM
08:50AM
Feb-17-22 03:02PM
Jan-21-22 10:49AM
Jan-19-22 10:46AM
Jan-12-22 11:25AM
Jan-08-22 06:13AM
Jan-06-22 08:00AM
Jan-05-22 04:05PM
Dec-23-21 10:15AM
Nov-29-21 04:05PM
Nov-15-21 07:24PM
09:00AM
Nov-08-21 10:08AM
Nov-07-21 06:38AM
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Faga DanielCEOMar 25 '24Sale21.423,00064,268749,087Mar 26 08:10 PM
Faga DanielCEOMar 22 '24Sale22.78145,9403,325,185752,087Mar 26 08:10 PM
LOUMEAU ERIC JCHIEF LEGAL OFFICERFeb 16 '24Option Exercise14.025,00070,1008,240Feb 21 05:38 PM
LOUMEAU ERIC JCHIEF LEGAL OFFICERFeb 16 '24Sale25.005,000125,0003,240Feb 21 05:38 PM
MULROY DENNISCHIEF FINANCIAL OFFICERJan 30 '24Sale23.633,06572,425964Feb 01 05:27 PM
Faga DanielCEOJan 08 '24Sale21.816,866149,747898,027Jan 09 07:05 PM
Lizzul Paul F.Chief Medical OfficerJan 08 '24Sale21.812,55455,70310,118Jan 09 07:08 PM
LOUMEAU ERIC JChief Legal OfficerJan 08 '24Sale21.812,30550,2723,240Jan 09 07:07 PM
MULROY DENNISChief Financial OfficerJan 08 '24Sale21.812,18047,5464,029Jan 09 07:06 PM
LOUMEAU ERIC JChief Legal OfficerJan 06 '24Option Exercise0.005,54505,545Jan 09 07:07 PM
Lizzul Paul F.Chief Medical OfficerJan 06 '24Option Exercise0.006,145012,672Jan 09 07:08 PM
MULROY DENNISChief Financial OfficerJan 06 '24Option Exercise0.005,24506,209Jan 09 07:06 PM
Faga DanielCEOJan 06 '24Option Exercise0.0017,8500904,893Jan 09 07:05 PM
LOUMEAU ERIC JChief Legal OfficerNov 22 '23Sale14.1988212,5160Nov 27 04:03 PM
MULROY DENNISChief Financial OfficerSep 18 '23Sale19.323,89575,237964Sep 18 06:12 PM
LOUMEAU ERIC JChief Legal OfficerSep 18 '23Sale19.323,89575,232882Sep 18 06:13 PM
Lizzul Paul F.Chief Medical OfficerSep 14 '23Sale19.482,10541,0056,527Sep 18 06:14 PM
LOUMEAU ERIC JChief Legal OfficerSep 14 '23Sale19.482,10541,0054,777Sep 18 06:13 PM
MULROY DENNISChief Financial OfficerSep 14 '23Sale19.482,10541,0054,859Sep 18 06:12 PM